Abstract: . . .  NOTES Advances in the Pharmacologic Treatment of Arteriosclerosis : What Does the Future Hold? Russell H. Samson, MD, FACS, RVT, Sarasota, FL 31st Global: Vascular and Endovascular Issues, Techniques and . . .
. . .  weight and stopping smoking) that can do the same thing at no cost and have other benefits as well. References 1. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary athero sclerosis in patients with acute coronary syn dromes: a randomized controlled trial. JAMA 2003;290:2292300. 2. Wald NJ, Law MR. Strategy to reduce cardiovas- cular disease by more than 80%. . . .
. . .  has also been shown to be associated with exceptionally elevated levels of HDL cholesterol and apo A-I owing to delayed catab- olism of HDL. This led to the concept that inhibition of CETP might be a pharmacologic strategy for rais- ing HDL. The impact of CETP inhibition on athero- sclerosis in humans remains to be determined. However, CETP inhibitors are already in clinical tri- als (Torcetrapib). . . .
. . .  of infusion. 1 In the study, 36 patients who had had heart attacks or severe chest pain received weekly intravenous infusions of the substance for 5 weeks. Eleven patients received place- bo treatments. At 6 weeks, imaging tests showed that the patients receiving the synthetic protein had intravas- cular ultrasonographic evidence of a 4.2% reduction in plaque buildup in their coronary arteries. . . .
--1766,4,221,1873,8830